Grab a FREE copy of the SpaceX Investing Blackbook here:

Back in April, I shared a rather unusual idea with members of my private community.

The thesis was simple:

A flood of investors looking for exposure to SpaceX could accidentally pile into SPCE instead.

As strange as it sounded, that's exactly what happened.

Just recently, SPCE surged roughly 300% in a week, creating a sizable opportunity for anyone who got in early.

Now, that was a unique situation.

What I want to show you today is something much more deliberate.

I'm about to set you right in the middle of a massive investing stampede.

And all you need to do is pick up a FREE copy of my SpaceX Investing Blackbook.

In The FREE Report You’ll See:

• How to Capitalize On SpaceX BEFORE the IPO hits
• The space ticker (NOT SpaceX) that Goldman Sachs, Blackrock and Morgan Stanley are all loading up on
• The one rare resource miner that Elon’s entire empire (including Tesla) depends on.
• The 1 trade 90% of retail investors will get wrong on IPO day
• The chip supplier that Starlink satellites can't function without

No guarantees when it comes to trading, of course.

But if you're looking for the next opportunity tied to the biggest IPO in the world...

You'll want to take a look.

You can access the Blackbook right here.

Till the next trade...

Lance Ippolito

SMX: Can Molecular Tracking Technology Become the Next Moonshot?

Written by Chris Markoch. Posted: 6/12/2026.

It wasn’t that long ago that investing in space seemed like a moonshot rooted in more hype than hope. Today, the SpaceX (NASDAQ: SPCX) IPO is capturing investor attention for good reason. SpaceX is the biggest name in a sector that’s now starting to deliver on its promise.

Early investors are being rewarded for their risk. For speculative investors willing to look ahead at a potentially lucrative industry, it may be time to consider SMX (NASDAQ: SMX)—the company previously known as Security Matters.

The Foundational Layer of the Circular Economy

SMX is attempting to carve out a leadership position in the circular economy by solving the problem of authenticity in global supply chains. Specifically, it aims to verify where something is, where it came from, and whether it has been tampered with.

Think about a bar of gold, a barrel of oil, or a batch of recycled plastic. Today, the only proof of origin is paperwork. However, those documents can be falsified, lost, or separated from the product.

SMX’s answer is to make the material itself carry its own unforgeable ID. The company’s platform embeds invisible molecular markers directly into physical materials.

This allows items to carry a persistent identity that can be detected and verified throughout their lifecycle. Every handoff, every processing step, and every shipment can be recorded and stored immutably on blockchain ledgers, creating a transparent chain of custody that follows the material from raw extraction to deployment.

Equally important, the molecular markers cannot be removed or faked.

How Does SMX Translate Opportunity Into Revenue?

The company has four avenues to monetize its technology:

• Licensing the technology to manufacturers and commodity producers

• Selling proprietary reader hardware

• Subscription or SaaS fees for access to the digital verification platform

• Project-based revenue: pilot programs, integration projects, and proof-of-concept contracts with enterprise partners

However, by its own admission, SMX has reported zero revenue in all of the SEC filings it’s made to date. Furthermore, the company doesn’t list any commercial customers or contracts. This comes at a time when losses are mounting, and shareholder equity has fallen about 90% between FY2023 and the middle of 2025.

The Challenge: A Decade in Business With No Revenue

As much as governments are cracking down on sustainability claims, recycled content, and supply chain transparency, these issues haven’t yet reached critical mass. That’s a risk for investors because SMX is a 10-year-old company that’s still at the pre-revenue stage.

Complicating matters even more is that the company recently executed a reverse stock split with a ratio of 2.285:1. As reverse splits go, that’s not egregious, but it does underscore the risk investors take on when dealing with a company that is not yet profitable at a time when competition for capital has increased.

On the other hand, prior to the reverse split, the company awarded two million restricted stock units to its executive team. That’s not an action that suggests a company with going-concern risk.

SMX Is a Binary Bet on Adoption and Execution

SMX is not for every investor, but it checks many of the boxes that attract speculative capital. It has a novel technology, a large addressable market, and regulatory tailwinds building behind it.

That said, investors need to go in with their eyes open. Short interest in SMX has been elevated and volatile. As of May 29, roughly 63% of the float was sold short, most likely in anticipation of the reverse split. High short interest cuts both ways. It reflects skepticism from professional traders, but it also creates the conditions for a short squeeze if positive catalysts emerge.

The more fundamental concern is competition. SMX is not operating in a vacuum. Applied DNA Sciences has a similar molecular tagging platform and already has paying customers in the textile industry. Authentix, a private firm, has been embedding chemical markers into fuels and pharmaceuticals for national governments and regulators for years. Neither has "won" the market, but both have commercial revenue that SMX currently lacks.

For investors, the question is whether SMX can convert its pipeline of pilots and proof-of-concept agreements into actual revenue before its balance sheet forces it to raise capital again on unfavorable terms. With a current ratio of 0.59—meaning current liabilities exceed current assets—that clock is ticking.

SMX is a binary bet. The stock is being ignored by analysts and institutional investors. If the circular economy regulatory wave accelerates and SMX lands even one major commercial contract, the story changes quickly. However, if it doesn’t, the accumulated deficit keeps growing and dilution risk rises. It’s a cheaper moonshot than SpaceX, but the risks are real.